Future Science Group

In this episode, supported by BrandTech, returning guest Rob Vries, CEO of HUB organoids (Utrecht, The Netherlands), fills us in on the advancement of 3D cell cultures and organoids over the last 2 years, starting off by documenting how the pandemic impacted their development and uptake. We also discuss how the recent FDA Modernization Act, removing the requirement for drug candidates to be tested on animals, has impacted the drive for improved models, the key techniques available to analyze them and what still needs to change for 3D cell cultures to fully replace animal models in the lab. Listen today to find out which resources can help you begin to work with 3D cell cultures, their most exciting recent applications and how issues of reproducibility are currently being addressed in the field. Contents:Intro: 00:00-00:50How COVID-19 impacted the uptake and development of 3D cell cultures: 00:50-02:05Key developments in 3D cell culture technology in the last 2 years: 02:05-03:00Intestinal organoids and the

In this episode of Editor’s Picks, presented by guest-host Grace Tyrrell, learn about how the need for vaccine refrigeration could be on the way out, a new chemical approach that may aid in the fight against antibiotic resistance and the use of AI algorithms as a potential cure for drug-resistant epilepsy.

Welcome to OC talks, a podcast series exploring the latest advancements in oncology. I’m your host, Jade Parker, Oncology Central’s Senior Editor. In this episode, supported by Sengenics, we will be exploring the importance of autoantibodies in the development of cancer as well as how they can be used in the early detection of tumors. Joining me for this episode is Field Application Scientist Joseph Miseirvitch from Sengenics, a precision medicine company working to improve patient outcomes for physiologically relevant, data-guided decision making.

BZ PPD Spotlight Podcast: an interview with Cyrille Bonhomme by Future Science Group

In this episode of Talking Techniques, supported by Bio-Rad, we discuss a key component of many gene therapies: recombinant adeno-associated viruses (rAAVs) and their production. These viruses act as efficient, accurate delivery vesicles for the gene therapy’s plasmid. Speaking to Associate Director of Biopharma Product Marketing at Bio-Rad Laboratories, Mark White, we take a look the different expression systems used for their production and compare their advantages, before looking at some of the challenges involved in the production rAAVs, such as host cell contamination. Discover the tools that can help minimize host cell contamination and differentiate between nuclease resistant and nuclease reactive contaminant DNA and find out about some of the most exciting developments in rAAV technologies.   Contents:The role of rAAVs in gene therapies: 00:40-02:15 The production of rAAVs and gene therapies: 02:15-03:30 Why are HEK cells so popular for cell therapy production? 03:30-05:45 HEK vs

In this episode of Editor’s Picks, hosted by our Assistant Editor Aisha Al-Janabi, learn about recent concerns over the validity of a pivotal Alzheimer’s disease study, how researchers answered a question about the heart dating back to the 1600s and a laser-based diamond sensing technology that improves magnetoencephalography precision.

In many regions of the world, HPV and its association with cervical cancer is a well-known but rarely considered issue, after the rollout of the HPV vaccine in the late 2000s. However, while this rollout significantly impacted cervical cancer rates where it was implemented, it was not universal and in many areas of the world HPV induced cervical cancer remains a critical issue. Cervical cancer is the leading cause of death for people with a cervix living in poverty in low-resource regions and on the continent of Africa, it is estimated that in 2020 as many people with a cervix died of cervical cancer as COVID-19. In this episode of Talking techniques, supported by Oxford Nanopore, Senior Investigator Michael Dean and Post-baccalaureate Fellow Nicole Rossi, from the NIH’s National Cancer Institute (MD, USA), discuss their research into the relationship between HPV and cervical cancer. Expounding on the points mentioned above, they reveal the tremendous insights into cancer and immunology still to be gained,

Recently, the Alliance for Artificial Intelligence in Healthcare (AAIH) published "The Lifecycle of an AI System in Healthcare", a whitepaper defining what healthcare is and provides guidelines on implementing artificial intelligence (AI) and machine learning (ML) in this setting. In this episode of Talking Techniques, we speak with Oscar Rodriguez, a board member at AAIH and one of the authors of this whitepaper, to find out more about what the lifecycle of AI is, the importance of having guidelines when applying AI or ML in healthcare and what the future holds for this type of computer modeling. Contents: Intro: 00:00 - 00:45What are some of the ways that AI is used in healthcare? 00:45 - 5:04What are the current limitations of using AI in healthcare settings? 5:04 - 9:28The lifecycle of an AI system: 9:28 - 14:04How did you develop these guidelines for AI in healthcare? 14:04 - 17:28Summary of the guidelines from the white paper: 17:28 - 19:09Do you think some of these guidelines could be applicable to A

Recently, the Alliance for Artificial Intelligence in Healthcare (AAIH) published "The Lifecycle of an AI System in Healthcare", a whitepaper defining what healthcare is and provides guidelines on implementing artificial intelligence (AI) and machine learning (ML) in this setting. In this episode of Talking Techniques, we speak with Oscar Rodriguez, a board member at AAIH and one of the authors of this whitepaper, to find out more about what the lifecycle of AI is, the importance of having guidelines when applying AI or ML in healthcare and what the future holds for this type of computer modeling. Contents: Intro: 00:00 - 00:45What are some of the ways that AI is used in healthcare? 00:45 - 5:04What are the current limitations of using AI in healthcare settings? 5:04 - 9:28The lifecycle of an AI system: 9:28 - 14:04How did you develop these guidelines for AI in healthcare? 14:04 - 17:28Summary of the guidelines from the white paper: 17:28 - 19:09Do you think some of these guidelines could be applicable to A

Welcome to our newest podcast series, Editor's Picks, where we'll round up the latest life science news from BioTechniques. In this bitesize podcast, we've got everything from the history of cephalopods in neuroscience research to recent advancements against antibiotic-resistant bacteria.

Mitigation strategies for the biological matrix supply chain: an interview with Mark O'Dell by Future Science Group

In this episode, supported by Zymo Research, guest host Georgia Bickerton explores NGS data and how bioinformatic pipelines and workflows can be optimized to make NGS data more accessible. To do this she speaks with Jeffrey Bhasin, Director of Informatics at Zymo Research, who discusses the key issues of reproducibility in bioinformatics, the selection of methods available to analyze different datasets and to investigate different aspects of these data. Listen today to discover the techniques available to help increase the portability and reproducibility of fine-tuned bioinformatics workflows and to streamline the application of these workflows. Bhasin also reveals how these 'workflow management' technologies can enable more global, collaborative approaches to bioinformatics workflow construction and begin to increase the automation and accessibility of bioinformatics workflows. Contents: Introduction: 00:00-00:55 How the rise of NGS has impacted the field of bioinformatics: 00:55-01:35 Issues of reproduc

ADA assay development: a podcast interview with Lynn Kamen by Future Science Group

The key diagnostic and prognostic information locked away in cell-free nucleic acids (cfNAs) has become increasingly accessible due to developments in genetic and epigenetic profiling techniques. These advances have engendered the rise of liquid biopsy techniques, which capture and analyze cfNAs from samples such as blood, saliva, urine and feces, in diagnostics and basic disease research. However, challenges remain in the detection and analysis of these nucleic acid fragments, in part due to their low abundance and fragile nature. In this episode, Ayla Maunighan-Peter, Epigenetics Product Specialist at Zymo research (CA, USA), details the utility of these molecules, the challenges associated with their development and implementation of liquid biopsies and their use in both basic research and diagnostic spaces. For an insight into how cfNAs can be used to identify novel drug targets, impact diagnostics development and be used to help soothe the organ shortage crisis, listen today! Contents: Intro: 00:

The key diagnostic and prognostic information locked away in cell-free nucleic acids (cfNAs) has become increasingly accessible due to developments in genetic and epigenetic profiling techniques. These advances have engendered the rise of liquid biopsy techniques, which capture and analyze cfNAs from samples such as blood, saliva, urine and feces, in diagnostics and basic disease research. However, challenges remain in the detection and analysis of these nucleic acid fragments, in part due to their low abundance and fragile nature. In this episode, Ayla Maunighan-Peter, Epigenetics Product Specialist at Zymo research (CA, USA), details the utility of these molecules, the challenges associated with their development and implementation of liquid biopsies and their use in both basic research and diagnostic spaces. For an insight into how cfNAs can be used to identify novel drug targets, impact diagnostics development and be used to help soothe the organ shortage crisis, listen today! Contents: Intro: 00

In this Tech Blast episode, we discuss preclinical models of non-alcoholic fatty liver disease with Gareth Guenigault, Lead Scientist of Services at CN Bio (Cambridge, UK). Gareth provides an overview of non-alcoholic steatohepatitis (NASH) therapeutic landscape and explains how incorporating organ-on-a-chip models into drug discovery workflows can improve this landscape. Get Gareth’s expert insight into the field and discover how to develop liver-on-a-chip NASH models, tips for analyzing the resultant data, and the future of organ-on-a-chip technologies. Contents: Introduction: 00:00–00:30 Pathology and prevalence of NASH: 00:30–01:50 Challenges faced when developing drugs for NASH: 01:50–03:40 An overview of organ-on-a-chip models: 03:40–05:05 Liver-on-a-chip models for NASH: 05:05–07:05 Incorporating organ-on-a-chip into drug discovery workflows: 07:05–08:45 Accessing liver-on-a-chip and NASH models: 08:45–09:45 The NASH-in-a-box workflow: 09:45–10:45 Gareth’s tips for analyzing the data: 10:45–12:15 The

FON-2021-1277 OCTalks by Future Science Group

In this episode, we discuss recombinant proteins: what are they and what are they used for? BioTechniques Editor Tristan Free speaks to Amy Sheng, Technical Account Manager at Sino Biological, who explains the history of recombinant proteins and how protein modeling techniques such as AlphaFold are changing their development. Find out how monoclonal antibodies have been used through the COVID-19 pandemic and how we may overcome challenges in production, upscaling and more in this episode of Talking Techniques.  Contents:Introduction 00:00-01:26What are recombinant proteins and what are they used for? 01:26 – 02:42How were they first developed? 02:42 – 03:50Since initial development has recombinant antibody development progressed today? 03:50 – 05:57What are the advantages of utilizing the more traditional mouse monoclonal antibodies? 05:57 – 07:11Are recombinant antibodies used in more specialist applications and are they more likely to be used in therapeutics? 07:11 – 09:47How have AI systems like

In this Tech Blast episode, we discuss generating, standardizing and sharing microbiome data with Raul Cano, Chief Scientific Officer at The BioCollective. Raul provides a brief overview of the reproducibility crisis and explores how the use of standards and databases can address the challenges it poses. Get Raul’s insight into the field and discover the steps that can be taken to make microbiome research accessible and reproducible. Contents: Introduction: 00:00–00:40 Overview of the reproducibility crisis: 00:40–02:25 The importance of standards for microbiome data: 02:25–05:05 Sharing microbiome data: 05:05–07:10 Comparing microbiome databases: 07:10–08:20 The significance of metadata: 08:20–08:50 How databases can enhance the use of standards: 08:50–10:05 Databases help standardize microbiome research: 10:05–10:45 Benefits of sharing data: 10:45–11:40

In this '3D and tea' interview, we speak to Dolores Serrano and Katerina Lalatsa all about the potential of utilizing 3D printing in cancer studies.